Copyright
©The Author(s) 2020.
World J Gastroenterol. Nov 21, 2020; 26(43): 6853-6866
Published online Nov 21, 2020. doi: 10.3748/wjg.v26.i43.6853
Published online Nov 21, 2020. doi: 10.3748/wjg.v26.i43.6853
Table 2 Correlation of immunoreactivity of doublecortin-like kinase 1/leucine-rich repeat-containing G-protein-coupled receptor 5 with clinicopathological features
| Clinicopathologic characteristics | n (%) | DCLK1/Lgr5 phenotypes | P value | |||
| DCLK1Low /Lgr5Low | DCLK1Low /Lgr5High | DCLK1High /Lgr5Low | DCLK1High /Lgr5High | |||
| Age (yr) | ||||||
| ≤ 49 | 49 (53) | 23 (47) | 3 (6) | 10 (20) | 13 (27) | 0.890 |
| > 49 | 43 (47) | 18 (42) | 4 (9) | 11 (26) | 10 (23) | |
| Gender | ||||||
| Male | 52 (57) | 25 (48) | 4 (8) | 12 (23) | 11 (21) | 0.348 |
| Female | 40 (43) | 16 (40) | 3 (7) | 9 (23) | 12 (30) | |
| Depth of penetration | ||||||
| T3 | 18 (20) | 5 (28) | 1 (6) | 8 (44) | 4 (22) | 0.223 |
| T4 | 74 (80) | 36 (49) | 6 (8) | 13 (17) | 19 (26) | |
| Lymph node | ||||||
| N0 | 38 (41) | 17 (45) | 3 (8) | 10 (26) | 8 (21) | 0.858 |
| N1 | 41 (45) | 18 (44) | 4 (10) | 9 (22) | 10 (24) | |
| N2 | 13 (14) | 6 (46) | 0 (0) | 2 (15) | 5 (39) | |
| Tumor stage (TNM) | ||||||
| II | 38 (41) | 17 (45) | 3 (8) | 10 (26) | 8 (21) | 0.774 |
| III | 54 (59) | 24 (45) | 4 (7) | 11 (20) | 15 (28) | |
| Differentiation | ||||||
| Well/moderate | 66 (72) | 32 (48) | 5 (8) | 16 (24) | 13 (20) | 0.115 |
| Poor/mucinous | 26 (28) | 9 (35) | 2 (8) | 5 (19) | 10 (38) | |
| Tumour site | ||||||
| Left | 42 (46) | 22 (52) | 2 (5) | 10 (24) | 8 (19) | 0.187 |
| Right | 17 (18) | 4 (23) | 3 (18) | 3 (18) | 7 (41) | |
| Rectum | 33 (36) | 15 (46) | 2 (6) | 8 (24) | 8 (24) | |
| Postoperative adjuvant chemotherapy | ||||||
| Xeloda monotherapy | 7 (7) | 3 (43) | 1 (14) | 21 (29) | 22 (14) | 0.875 |
| FOLFOX regimen | 32 (35) | 15 (47) | 3 (9) | 5 (16) | 9 (28) | |
| XELOX regimen | 53 (58) | 23 (43) | 3 (6) | 14 (26) | 13 (25) | |
| CEA | ||||||
| Normal | 68 (74) | 33 (49) | 5 (7) | 12 (18) | 18 (26) | 0.238 |
| High | 24 (26) | 8 (33) | 2 (8) | 9 (38) | 5 (21) | |
| CA19-9 | ||||||
| Normal | 66 (72) | 29 (44) | 6 (9) | 16 (24) | 15 (23) | 0.710 |
| High | 26 (28) | 12 (46) | 1 (4) | 5 (19) | 8 (31) | |
| MSI | ||||||
| MSS | 89 (97) | 39 (44) | 7 (8) | 21 (25) | 22 (23) | 0.713 |
| MSI | 3 (3) | 2 (67) | 0 (0) | 0 (0) | 1 (33) | |
| Recurrence | ||||||
| Absent | 67 (73) | 30 (45) | 7 (10) | 14 (21) | 16 (24) | 0.374 |
| Present | 25 (27) | 11 (44) | 0 (0) | 7 (28) | 7 (28) | |
| Lung metastasis | ||||||
| Absent | 80 (87) | 33 (41) | 7 (9) | 19 (24) | 21 (26) | 0.365 |
| Present | 12 (13) | 8 (66) | 0 (0) | 2 (17) | 2 (17) | |
| Liver metastasis | ||||||
| Absent | 83 (90) | 35 (42) | 7 (9) | 20 (24) | 2 (25) | 0.478 |
| Present | 9 (10) | 6 (67) | 0 (0) | 1 (11) | 2 (22) | |
- Citation: Kang XL, He LR, Chen YL, Wang SB. Role of doublecortin-like kinase 1 and leucine-rich repeat-containing G-protein-coupled receptor 5 in patients with stage II/III colorectal cancer: Cancer progression and prognosis. World J Gastroenterol 2020; 26(43): 6853-6866
- URL: https://www.wjgnet.com/1007-9327/full/v26/i43/6853.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i43.6853